NCT04920383
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years to 80 Years (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with active central nervous system metastases
https://ClinicalTrials.gov/show/NCT04920383